BAVIS_1170x120_1-20

CutisPharma

CutisPharma acquires Silvergate Pharmaceuticals, unveils new name

CutisPharma acquires Silvergate Pharmaceuticals, unveils new name

WOBURN, Mass. – CutisPharma announced Wednesday its acquisition of Silvergate Pharmaceuticals and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals. “I am thrilled to announce the combination of two strong companies with a rich legacy meeting the needs of underserved patients, such as children and the elderly,” said Neal Muni,

CutisPharma launches First-Metoprolol unit-of-use prescription compounding kit

CutisPharma launches First-Metoprolol unit-of-use prescription compounding kit

WILMINGTON, Mass. —  CutisPharma announced the commercial availability of First-Metoprolol grape-flavored oral solution compounding kit. First-Metoprolol provides pharmacists with a convenient, high-quality, standardized way to compound an oral liquid metoprolol solution for patients who are not otherwise served by commercially available therapies, such as those who are unable to swallow solid oral dosing formulations. “We are pleased to announce that, effective

CutisPharma announces FDA approval for Firvanq

CutisPharma announces FDA approval for Firvanq

WILMINGTON, Mass. — CutisPharma reported that the U.S. Food and Drug Administration has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. “We are pleased to announce the FDA approval of Firvanq,” Neal Muni,  chief executive officer of CutisPharma said

CutisPharma grant to boost C. difficile awareness

CutisPharma grant to boost C. difficile awareness

WILMINGTON, Mass. — CutisPharma plans to award an unrestricted grant to the C Diff Foundation to further support its efforts to raise awareness of Clostridium difficile infection (C. difficile). A serious gastrointestinal infection, C. difficile — also known as C diff. — typically affects people who are on antibiotic therapy and/or have experienced a long-term hospitalization or

CutisPharma inaugurates new R&D center

CutisPharma inaugurates new R&D center

WILMINGTON, Mass. — CutisPharma has opened a new research-and-development center in Woburn, Mass., to house the specialty pharmaceutical company’s expanding R&D team. CutisPharma said the new center will provide office and laboratory space to facilitate the development of products for Food and Drug Administration approval under its RM Therapeutics subsidiary. “We are in the midst

CutisPharma appoints chief scientific officer

CutisPharma appoints chief scientific officer

WILMINGTON, Mass. — Steven Dinh has joined CutisPharma as executive vice president and chief scientific officer. CutisPharma said Monday that Dinh will play a key role at the company, overseeing its efforts to develop its pipeline of drugs for New Drug Application (NDA) submission to the Food and Drug Administration. “We are pleased to have

CutisPharma, Dr. Reddy’s announce API agreements

CutisPharma, Dr. Reddy’s announce API agreements

WILMINGTON, Mass. — CutisPharma has entered into active pharmaceutical ingredient (API) supply and joint development pacts with Dr. Reddy’s Laboratories Ltd. CutisPharma, which focuses on products for the prescription compounding market,  said Tuesday that it aims to advance several programs in its research and development portfolio — including RM-02, RM-03 and RM-06 — toward Food